Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-Term Treatment With the Oral Direct Thrombin Inhibitor Ximelagatran, Compared to Warfarin, as Stroke Prophylaxis in Patients With Atrial Fibrillation. A Long Term Follow-Up Study

NCT00206063 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00206063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00206063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-Term Treatment With the Oral Direct Thrombin Inhibitor Ximelagatran, Compared to Warfarin, as Stroke Prophylaxis in Patients With Atrial Fibrillation. A Long Term Follow-Up Study
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 1999
Completion date
April 30, 2006
Enrollment
220
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

stroke prevention in patients with atrial fibrillation